All In Biotech

Drug Trial Radar · NCT03964493

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in Adults

Last checked: Nov 20, 2026Latest source record: Dec 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Apr 20, 2019

Primary completion

Sep 28, 2020

Study completion Sep 28, 2020

Sponsor

Lead sponsor
TenNor Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
May 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.

Conditions

  • Skin and Subcutaneous Tissue Bacterial Infections
  • Gram-Positive Bacterial Infections

Interventions

  • TNP-2092Drug

    TNP-2092 100mg/vial

  • VancomycinDrug

    Vancomycin 1g/vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) PopulationTime frame: 48 to 72 hours after the first dose of study treatment
  2. Early Clinical Response at the Early Assessment Visit in the Modified Intent-to-Treat (mITT) PopulationTime frame: 48 to 72 hours after the first dose of study treatment
  3. Early Clinical Response at the Early Assessment Visit in the Micro-Intent-to-Treat (Micro-ITT) PopulationTime frame: 48 to 72 hours after the first dose of study treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • eStudy Site

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.